
|Videos|March 9, 2022
Urology Times 50 Innovations Series: Active surveillance for prostate cancer
Author(s)Urology Times staff
"Active surveillance is an innovation because it's truly a departure from the idea that all prostate cancers or cancer, in general, needs to be treated," says Kara L. Watts, MD.
Advertisement
In this installment in Urology Times®' 50th Anniversary Innovation Celebration series, Kara L. Watts, MD, discusses the emergence and increasing uptake of active surveillance as a management strategy for men with prostate cancer. Watts, a member of the Urology Times® Editorial Council, is an assistant professor of urology at Montefiore Medical Center, Bronx, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5


















































